Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma

Annals of Oncology

Volumn 9, Issue 6, 1998, Pages 633-638

  Bailey, N P ^a,f   Stuart, N S A ^a   Bessell, E M ^b   Child, J A ^c   Norfolk, D ^c   Fletcher, J ^b   Grieve, R J ^d   Simmons, A V ^e   Barnard, D L ^e   Jack, A ^c   Farish, J ^c   Dunn, J ^a   Woodroffe, C M ^a   Stack, C ^a   Cullen, M H ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d WALSGRAVE HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

CHOP Mtx vs. CAPOMEt; Non Hodgkin's lymphoma; Randomised trial

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 7344231043     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008276700860     Document Type: Article

References (19)

1. Armitage JO, Fyfe M, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984; 2: 898-902.
2. Shipp MA, Harrington DP. Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
3. Cooper IA, Wolf MM, Robertson TI et al. Randomised comparison of MACOP-B with CHOP in patients with intermediate grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994; 12, 769-78.
4. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
5. Hryniuk W, Bush H. The importance of dose intensity in the chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281 8.
6. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596-602.
7. Longo DL, DeVita VT. Duffey P et al. Randomised trial of ProMace-Mopp vs. ProMACECytaBOM in stage II-IV aggressive non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1987; 6: 206.
8. Child JA, Barnard DL, Cartwright SC et al. A pilot study of cyclical chemotherapy with high dose methotrexate and CHOP (MTX-CHOP) in poor prognosis non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1983; 11: 153-8.
9. Skarin AT, Canellos GP, Rosenthal DS et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91-8.
10. Taylor RE, Mcelwain TJ, Barrett A et al. Etoposide as a single agent in relapsed advanced lymphomas. A phase I study. Cancer Chemother Pharmacol 1982; 7: 175-7.
11. Hansen MM, Bloomfield CD. Jorgensen J et al VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone in the treatment of non-Hodgkin's lymphomas. Cancer Treat Rep 1980; 64: 1135-7.
12. Carbone PP, Kaplan HS, Mushoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860 1.
13. Stansfeld A, Diebold J, Noel H et al. Updated Kiel classification for lymphomas. Lancet 1988; (i): 292-3.
14. Coiffier B, Bryon PA, Berger F et al. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80), J Clin Oncol 1986; 4: 147-53.
15. Longo DL, Devita VT, Duffey PL et al. Superiority of ProMACE-CytoBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomsied trial. J Clin Oncol 1991; 9: 25-38.
16. Fisher RI, Gaynor ER. Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
17. Gordon LI, Harrington D, Anderson J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-9.
18. Linch DC, Vaughan Hudson B, Hancock BW et al. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British National Lymphoma Investigation report. Br J Cancer 1996; 74: 318-22.
19. Bessell EM, Coults A, Fletcher J et al. Non-Hodgkin's lymphoma in elderly patients. A phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate or high-grade histology. Eur J Cancer 1994; 30A (9): 1337-41.